Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: A meta-analysis

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 1-2, 2006, Pages 25-32

  Mosholder, Andrew D ^a   Willy, Mary ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ARTICLE; AUTOMUTILATION; CHILD; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG INDICATION; HUMAN; INCIDENCE; META ANALYSIS; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTEMATIC REVIEW;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; HUMANS; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS; SUICIDE, ATTEMPTED;

EID: 33645818754     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.25     Document Type: Article

References (22)

1. Beasley CM, Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN: Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. BMJ 303:685-692, 1991.
2. Brent DA: Antidepressants and pediatric depression-the risk of doing nothing. N Engl J Med 351:1598-1601, 2004.
3. Committee on Safety of Medicines. New Advice on Seroxat from the Committee on Safety of Medicines. June 10, 2003. Online document at: medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/seroxatqa10603. pdf
4. Committee on Safety of Medicines. Selective serotonin reuptake inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents, including a summary of available safety and efficacy data. December 10, 2003. Online document at: medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/ ssrioverview%5F101203.htm
5. Dubitsky G. Review and evaluation of clinical data: Placebo-controlled antidepressant studies in pediatric patients. FDA Center for Drug Evaluation and Research, 2004. Online document at: http://www.fda.gov/ohrms/dockets/ac/04/ briefing/2004-4065b1-08-TAB06-Dubitsky-Review.pdf
6. European Medicines Agency. European Medicines Agency finalises review of antidepressants in children and adolescents (press release). April 25, 2005. Online document at: www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf
7. Gunnell D, Ashby D: Antidepressants and suicide: What is the balance of benefit and harm. BMJ 329;34-38, 2004.
8. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P: Association between antidepressant prescribing and suicide in Australia, 1991-2000: Trend analysis. BMJ 326:1008, 2003.
9. Hammad T. Review and evaluation of clinical data. FDA Center for Drug Evaluation and Research. August 16, 2004. Online document at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf
10. Hammad T. Results of the analysis of suicidality in pediatric trials of newer antidepressants. FDA Center for Drug Evaluation and Research. September 13. 2004. Online document at: www.fda.gov/ohrms/dockets/ac/04/slides/2004- 4065S1_08_FDA-Hammad_files/frame.htm
11. Jick H, Kaye JA, Jick S: Antidepressants and the risk of suicidal behaviors. JAMA 292:338-343, 2004.
12. Khan A, Warner HA, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317, 2000.
13. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L: Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179-186, 1991.
14. Laughren TP. Background comments for February 2, 2004 Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Sub-committee of the Anti-Infective Drugs Advisory Committee (Peds AC). FDA Center for Drug Evaluation and Research. January 5, 2004. Online document at: www.fda.gov/ohrms/dockets/ac/04/briefing/4006B1_03_Background%20Memo %2001-05-04.htm
15. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D: Antidepressant treatment and the risk of fatal and nonfatal self-harm in first-episode depression: Nested case-control study. BMJ 330:389-393, 2005.
16. Olfson M, Shaffer D, Marcus SC, Greenberg T: Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:978-982, 2003.
17. Posner K. Suicidality classification project. September 13, 2004. Online document at: www.fda.gov/ohrms/dockets/ac/04/slides/2004-065S1_06_FDA- Posner_files/frame.htm
18. Storosum JG, van Zweiten BJ, van den Brink W, Gersons BPR: Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158:1271-1275, 2001.
19. Treatment for Adolescents With Depression Study Team: Fluoxetine, cognitive behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized, controlled trial. JAMA 292:807-820, 2004.
20. Tiecher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207-210, 1990.
21. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR: Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: A propensity-adjusted retrospective cohort study. CNS Drugs 18:1119-1132, 2004.
22. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004.